Filana Therapeutics
FLNA
79 hedge funds and large institutions have $66.1M invested in Filana Therapeutics in 2020 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 13 reducing their positions, and 9 closing their positions.
177% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 13
122% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 9
16% more funds holding
Funds holding: 68 → 79 (+11)
1.44% more ownership
Funds ownership: 27.35% → 28.79% (+1.4%)
15% less capital invested
Capital invested by funds: $77.4M → $66.1M (-$11.3M)
35% less call options, than puts
Call options by funds: $2.23M | Put options by funds: $3.45M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
CAAS Capital Management
New York
|
+$6.14M |
| 2 |
BlackRock
New York
|
+$4.69M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$4.65M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$4.02M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$3.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
Bleichroeder LP
New York
|
-$3.57M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$1.89M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.44M |
| 4 |
Renaissance Technologies
New York
|
-$1.29M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$796K |
FLNA Hedge Fund Activity: Q4 2020 in Review
79 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q4 2020, worth a combined $66.1M — down 15% from $77.4M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new FLNA positions and 9 closed out — a net gain of 11 holders — while 36 added to existing stakes and 13 trimmed.
The largest buyer was CAAS Capital Management, opening a new position worth an estimated $6.14M. The largest seller was Bleichroeder LP, cutting an estimated $3.57M.
- 79 institutional investors held Filana Therapeutics (FLNA) as of Q4 2020, up from 68 in Q3 2020.
- Funds reported $66.1M of Filana Therapeutics stock for Q4 2020, down 15% quarter-over-quarter.
- 20 funds opened new Filana Therapeutics positions in Q4 2020 and 9 closed out, a net change of +11 holders.
- The largest Filana Therapeutics buyer in Q4 2020 was CAAS Capital Management, an estimated $6.14M added.
- The largest Filana Therapeutics seller in Q4 2020 was Bleichroeder LP, an estimated $3.57M sold.
Based on aggregated 13F filings for Q4 2020.